Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, accounting
for 25% of all childhood cancers. In the United States, approximately 3000 children aged 1 …

In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent
childhood hematological malignancy, as well as the leading cause of childhood cancer …

Abstract Changes in gene dosage are a major driver of cancer, known to be caused by a
finite, but increasingly well annotated, repertoire of mutational mechanisms. This can …

As controversy exists regarding the prognostic significance of genomic rearrangements of
CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as …

Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic
subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date …

Novel biological subtypes and clinically important genetic aberrations (druggable lesions,
prognostic factors) have been described in B-other acute lymphoblastic leukemia (ALL) …

In childhood B-cell precursor acute lymphoblastic leukemia, cytogenetics is important in
diagnosis and as an indicator of response to therapy, thus playing a key role in risk …

Purpose Five-year overall survival (OS) for children with B-cell precursor acute
lymphoblastic leukemia (B-ALL) exceeds 90% with risk-adapted therapy. Age, initial WBC …

Somatic genetic abnormalities are initiators and drivers of disease and have proven clinical
utility at initial diagnosis. However, the genetic landscape and its clinical utility at relapse are …

Purpose To evaluate the effect on outcome of intensifying therapy for patients with acute
lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 …